Drugs / HYALURONIC ACID (NON-ANIMAL STABILIZED)
last change 5 days ago re-read 9 days ago

HYALURONIC ACID (NON-ANIMAL STABILIZED)

Developed for
osteoarthritis, knee
Investigated by
Medicis Aesthetics, Inc. · The Cleveland Clinic

Trials 2

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT00852241 Feb → Sep 2009 — The Cleveland Clinic Completed No outcome recorded
Phase 4 NCT00765583 Nov 2005 → Dec 2008 — Medicis Aesthetics, Inc. Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT01697423 Comparator Dec 2012 → Mar 2016 osteoarthritis, knee Assistance Publique Hopitaux De Marseille Completed No outcome recorded

Press releases naming this drug 18 releases

DateIssuerRelease
2026-10-06 Galderma R&D 30 years of Restylane®: reshaping the aesthetics field through science-led, patient-centric innovation galderma.com ↗
2026-09-16 Galderma R&D Galderma’s Restylane® Volyme™ demonstrates high effectiveness, satisfaction and a robust safety profile in Chinese patients with temple hollowing galderma.com ↗
2026-08-11 Galderma R&D Galderma receives European Union approval for Restylane® Shaype™: the first-and-only bone-mimicking hyaluronic acid injectable for facial shaping galderma.com ↗
2026-03-23 Galderma R&D Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing galderma.com ↗
2026-02-25 Galderma R&D Galderma announces triple approval of new state-of-the-art Restylane® syringe in the EU, the U.S., and Canada, reaffirming the company’s position at the forefront of Injectable Aesthetics galderma.com ↗
2026-02-11 Galderma R&D Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™ galderma.com ↗
2026-01-29 Galderma R&D Galderma unveils ‘Wake Up To Restylane’, underscoring Restylane as the ideal hyaluronic acid treatment for always-on natural beauty galderma.com ↗
2025-11-17 Galderma R&D ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline galderma.com ↗
2025-11-05 Galderma R&D Galderma receives U.S. FDA approval for Restylane® Lyft™ for the enhancement of the chin profile galderma.com ↗
2025-01-23 Galderma R&D IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership galderma.com ↗
2024-01-29 Galderma R&D The remarkable journey of Restylane, from the lab to the patient galderma.com ↗
2024-01-22 Galderma R&D Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region galderma.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as HYALURONIC ACID (NON-ANIMAL STABILIZED) ChEMBL registry synonym — accepted as the source's own label CHEMBL4594585 ↗
Known as durolane ClinicalTrials.gov intervention name — accepted as the source's own label NCT01697423 ↗
Known as Hyaluronan (non animal) ChEMBL registry synonym — accepted as the source's own label CHEMBL4594585 ↗
Known as Hyaluronic acid (nasha) ChEMBL registry synonym — accepted as the source's own label CHEMBL4594585 ↗
Known as Nasha ChEMBL registry synonym — accepted as the source's own label CHEMBL4594585 ↗
Known as Perlane ClinicalTrials.gov intervention name — accepted as the source's own label NCT00852241 ↗
Known as Restylane ClinicalTrials.gov intervention name — accepted as the source's own label NCT00765583 ↗